Can a patient be restarted on lisdexamfetamine (Vyvanse) 40 mg after a three‑month drug holiday?

Restarting Vyvanse 40 mg After a 3-Month Break

Yes, you can restart Vyvanse 40 mg after a 3-month break, but you should strongly consider re-titrating from a lower starting dose (30 mg) for safety and tolerability, particularly if the patient had any prior adverse effects or if there are concerns about cardiovascular tolerance.

Rationale for Re-titration

The FDA label for lisdexamfetamine demonstrates that clinical trials used a systematic dose-optimization approach starting at 30 mg/day for one week before advancing to 50 mg/day, with further increases to 70 mg/day as tolerated 111. This titration strategy was employed even in treatment-naive patients, suggesting it represents best practice for initiating or re-initiating therapy.

After a 3-month drug holiday, the patient's physiological tolerance to stimulant effects may have diminished. Drug holidays are known to potentially "resensitize" neurons to the acute pharmacological effects of stimulants by partially reversing adaptive changes from chronic pharmacological stimulation 2. This means the patient may experience more pronounced effects—both therapeutic and adverse—when restarting at their previous maintenance dose.

Clinical Decision Algorithm

If the patient previously tolerated 40 mg well with good efficacy and no significant adverse effects:

• You may restart at 40 mg directly
• Monitor closely for the first 1-2 weeks for cardiovascular effects (blood pressure, heart rate), sleep disturbance, appetite suppression, and mood changes
• Have a lower threshold to reduce dose if adverse effects emerge

If the patient had any prior tolerability issues, cardiovascular concerns, or significant comorbidities:

• Start at 30 mg for 1 week
• Advance to 40 mg in week 2 if tolerated
• This approach mirrors the FDA-approved titration schedule 11

If the patient is uncertain about restarting or had marginal benefit previously:

• The 3-month break provides an opportunity to reassess whether medication is still needed
• Consider starting at 30 mg to re-establish baseline response before advancing

Important Safety Considerations

Stimulant medications require careful monitoring during initiation and dose adjustments 33. After a drug holiday, you should:

• Assess cardiovascular status: Check blood pressure and heart rate at baseline and within the first week of restarting
• Monitor for common adverse effects: The most frequent side effects with lisdexamfetamine include dry mouth, decreased appetite, insomnia, headache, and irritability 45
• Weekly contact during re-initiation: Maintain telephone or in-person contact weekly during the first 2-4 weeks to assess response and tolerability 3
• Use rating scales: Systematic assessment of target symptoms helps distinguish therapeutic response from adverse effects 3

Evidence on Drug Holidays

Drug holidays from ADHD medication are common (25-70% of families) and serve multiple purposes including testing whether medication is still needed and managing side effects 6. Weekend holidays during methylphenidate use have been shown to reduce insomnia and appetite suppression without significant symptom rebound 7. However, a 3-month break is substantially longer than typical weekend or summer holidays studied in the literature.

The randomized withdrawal study in the FDA label showed that patients who responded to lisdexamfetamine and then discontinued had significantly higher relapse rates compared to those who continued treatment 11. This suggests that after a prolonged break, symptoms may have returned, making re-initiation appropriate if clinically indicated.

Common Pitfalls to Avoid

• Don't assume previous tolerance persists: A 3-month break may reset physiological adaptation
• Don't skip cardiovascular monitoring: Stimulants can increase blood pressure and heart rate, and this risk may be heightened after a break
• Don't ignore the opportunity to reassess: Use this natural break point to confirm the medication is still needed and that the dose was optimal
• Don't restart without discussing adherence: Understand why the 3-month break occurred to address potential adherence barriers 8

The conservative approach of re-titrating from 30 mg balances safety with the goal of rapidly achieving therapeutic benefit, and aligns with FDA-approved dosing strategies used in clinical trials.